NCT05579925View on ClinicalTrials.gov

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 7, 2022

Primary Completion Date

July 28, 2023

Study Completion Date

July 28, 2023

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

CM310

CM310 600 mg + 300 mg, subcutaneous injection

Trial Locations (1)

Unknown

Beijing Children's Hospital Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05579925 - A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis | Biotech Hunter | Biotech Hunter